Examples of Broad RNAi Intellectual Property in a sentence
Novartis grants Alnylam a worldwide, non-exclusive, sublicenseable (solely to Controlled Contractors) license under such jointly-created IP that is Broad RNAi Intellectual Property, to engage in any and all research activities directed to human, veterinary or agricultural applications.
Once Novartis acquires the Adoption License, Alnylam will periodically deliver to Novartis all Broad RNAi Intellectual Property.
In the course of acquiring or licensing additional Broad RNAi Intellectual Property or any other Alnylam Intellectual Property covering a Collaboration Product, Alnylam must use its best efforts to ensure that such rights include the right to sublicense to Novartis such Broad RNAi Intellectual Property or other Alnylam Intellectual Property.
In the course of acquiring or licensing additional Broad RNAi Intellectual Property or any other Alnylam Intellectual Property Covering a Collaboration Product, Alnylam shall use its best efforts to ensure that such rights include the right to sublicense to Novartis such Broad RNAi Intellectual Property or any other Alnylam Intellectual Property Covering a Collaboration Product.
Novartis hereby grants to Alnylam a worldwide, non-exclusive, royalty-free right and license (sublicenseable solely to Controlled Contractors) under the Novartis Sole Inventions that, absent this Section 6.1(b), would have been Joint Intellectual Property that is Broad RNAi Intellectual Property, to engage in any and all research activities directed to the Field.
Following the Adoption Date, on a periodic basis as agreed by the Parties, and promptly following Novartis's reasonable request from time to time, Alnylam shall deliver to Novartis, for no additional consideration, all Broad RNAi Intellectual Property that is necessary or useful to the exercise of Novartis's rights under the Adoption License.
In connection with Novartis's bona fide consideration of acquiring the Adoption License, Alnylam shall afford Novartis and its attorneys and authorized representatives reasonable access to all relevant Patent Rights files, contracts, correspondence, records and Patent personnel of Alnylam and its Affiliates in order to permit Novartis to conduct due diligence with respect to the Broad RNAi Intellectual Property.
If Novartis so notifies Alnylam that such Target is not the subject of a Dedicated Novartis Program, then Alnylam may grant to such Pre-Existing Alliance Party the relevant rights under Broad RNAi Intellectual Property with respect to such Target, and Novartis's rights under Sections 3.1(a) or (c) shall be subject to such Pre-Existing Alliance Party's rights with respect to such Target.
If Novartis so notifies Alnylam that such Target is the subject of a Dedicated Novartis Program, Alnylam shall not grant to such Pre-Existing Alliance Party the requested rights under the Broad RNAi Intellectual Property with respect to such Target.
Furthermore, a qualitative environmental impact assessment (EIA) was undertaken for both phases of construction and exploitation.